ClearPoint Neuro (NASDAQ:CLPT) Announces Earnings Results

ClearPoint Neuro (NASDAQ:CLPT) posted its quarterly earnings results on Wednesday. The company reported ($0.24) earnings per share for the quarter, topping analysts’ consensus estimates of ($0.32) by $0.08, FiscalAI reports. ClearPoint Neuro had a negative return on equity of 188.09% and a negative net margin of 81.76%. The company had revenue of $12.07 million during the quarter, compared to the consensus estimate of $12.30 million.

Here are the key takeaways from ClearPoint Neuro’s conference call:

• Third-quarter revenue rose 36% year over year to $12.1 million, led by 59% growth in neurosurgery navigation revenue and 68% growth in capital equipment and software revenue, including contributions from IRRAflow.
• ClearPoint reported its largest-ever capital sales quarter and cited a record pipeline of hospitals preparing for cell and gene therapy trials. Management expects multiple partner Phase III trials to initiate or expand over the next 12–15 months.
• UniQure’s AMT-130 Huntington’s disease gene therapy remains a major potential catalyst; if the FDA accepts the BLA and the review proceeds successfully, ClearPoint expects to pursue a companion 510(k) with possible commercial approval in mid-to-late 2027.
• Gross margin declined to 58% from 63% because of start-up overhead at ClearPoint Advanced Laboratories and amortization from acquired intangible assets. The company also used its ATM facility to raise $22 million, creating shareholder dilution, while reporting $20.1 million of operational cash burn through the first nine months.
• Management expects continued front-loaded investment in the CAL facility, IRRAflow product launches, robotics, focused ultrasound, and clinical staffing, although it expects operating leverage to gradually reduce cash burn over the next four to six quarters. The company characterized mid-teens revenue growth as a reasonable early view for 2027 but has not issued formal guidance.

ClearPoint Neuro Stock Performance

NASDAQ CLPT traded up $0.39 during trading on Thursday, hitting $10.95. The company’s stock had a trading volume of 462,354 shares, compared to its average volume of 712,472. The firm has a market cap of $333.87 million, a P/E ratio of -9.22 and a beta of 1.29. ClearPoint Neuro has a 52 week low of $8.27 and a 52 week high of $24.98. The firm has a 50 day moving average price of $12.70 and a 200 day moving average price of $13.04. The company has a quick ratio of 3.89, a current ratio of 4.74 and a debt-to-equity ratio of 4.66.

Analyst Ratings Changes

Several research analysts have recently commented on the stock. Lake Street Capital set a $25.00 price target on shares of ClearPoint Neuro in a research note on Tuesday, August 4th. Weiss Ratings reissued a “sell (d-)” rating on shares of ClearPoint Neuro in a research report on Thursday, October 15th. Wall Street Zen lowered ClearPoint Neuro from a “sell” rating to a “strong sell” rating in a report on Saturday, August 8th. Finally, Stifel Nicolaus reduced their price target on ClearPoint Neuro from $22.00 to $18.00 and set a “buy” rating for the company in a research report on Thursday. Two analysts have rated the stock with a Buy rating and one has issued a Sell rating to the company’s stock. According to data from MarketBeat, ClearPoint Neuro presently has a consensus rating of “Hold” and an average target price of $24.33.

Key Stories Impacting ClearPoint Neuro

Here are the key news stories impacting ClearPoint Neuro this week:

• Positive Sentiment: ClearPoint Neuro reported a third-quarter loss of $0.24 per share, narrower than the analyst consensus loss of $0.32. The result also improved from a $0.21 loss in the year-earlier quarter on an adjusted comparison cited by Zacks. ClearPoint Neuro Reports Q3 Loss, Misses Revenue Estimates
• Positive Sentiment: The earnings release and conference call give investors updated information on ClearPoint Neuro’s operating performance and outlook. The company’s strong liquidity ratios may provide some flexibility as it continues investing while unprofitable. ClearPoint Neuro Reports Third-Quarter Earnings Results
• Neutral Sentiment: ClearPoint Neuro’s Q3 earnings call transcript may provide additional context on revenue trends, business execution and management’s expectations, but no specific new guidance is identified in the supplied reports. ClearPoint Neuro Q3 2026 Earnings Call Transcript
• Negative Sentiment: Quarterly revenue of approximately $12.07 million missed analysts’ $12.30 million estimate. ClearPoint Neuro also remains deeply unprofitable, reporting a negative net margin and negative return on equity, which limits the benefit of the EPS beat. ClearPoint Neuro Earnings Results
• Negative Sentiment: Stifel lowered its price target to $18, signaling reduced near-term expectations even though the revised target remains above the recent share price. Stifel Lowers ClearPoint Neuro Price Target
• Negative Sentiment: Pomerantz LLP is investigating potential claims on behalf of ClearPoint Neuro investors after a reported trial setback. The investigation creates legal and reputational uncertainty and may weigh on the stock. Pomerantz Investor Alert

ClearPoint Neuro Company Profile

ClearPoint Neuro, Inc is a medical technology company that develops and commercializes platforms for minimally invasive procedures involving the brain. Its technology is designed to help physicians plan, navigate and deliver treatments with real-time magnetic resonance imaging (MRI) guidance, supporting more precise access to targeted areas of the brain.

The company’s principal product is the ClearPoint Neuro Navigation System, which uses specialized software, instruments and accessories to guide neurosurgical procedures inside an MRI scanner.